Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
- Conditions
- Actinic Keratoses
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Novoxel Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05365386
- Locations
- 🇮🇱
Rabin Medical Center, Ha'Sharon Campus, Petach Tikva, Israel
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
- Conditions
- Dry EyeMeibomian Gland DysfunctionDry Eye Syndromes
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Novoxel Ltd.
- Target Recruit Count
- 109
- Registration Number
- NCT05162261
- Locations
- 🇺🇸
Gordon Schanzlin New Vision Institute, La Jolla, California, United States
🇺🇸Visionary Research Institute, Newport Beach, California, United States
🇺🇸Moyes Eye Center, Kansas City, Missouri, United States
Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction
- Conditions
- Dry Eye SyndromesDry EyeMeibomian Gland Dysfunction
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novoxel Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04889950
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
Clinical Study Evaluating the Safety and Effectiveness of The Tixel Fractional System in The Treatment of Periorbital Wrinkles
- Conditions
- PeriorbitalFractionalResurfacingWrinkleTixel 2
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Novoxel Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT04639713
- Locations
- 🇺🇸
Physicians Laser and Dermatology Institute, Chicago, Illinois, United States
🇺🇸Laser & Skin Surgery Center of New York, New York, New York, United States
🇮🇱Rabin Medical Center, Ha'Sharon Campus, Petach Tikva, Israel
Evaluation of The Efficacy and Safety of Tixel Treatment for the Treatment of Facial and/or Scalp Actinic Keratoses
- Conditions
- Actinic Keratoses
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Novoxel Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04527653
- Locations
- 🇮🇱
Rabin Medical Center, Ha'Sharon Campus, Petach Tikva, Israel
- Prev
- 1
- 2
- Next
News
Novoxel and GPOphtho Partner to Expand Access to FDA-Cleared Tixel Device for Dry Eye Treatment Across US
Novoxel Inc. and GPOphtho have finalized a strategic agreement to expand access to the Tixel device family for treating dry eye and aesthetic procedures nationwide.